Prime Medicine (PRME) EBT (2021 - 2026)
Prime Medicine's (PRME) quarterly EBT came in at -$228.7 million in Q1 2026, down 340.77% YoY from $95.0 million in Q1 2025, and down 381.22% on a QoQ basis from -$47.5 million in Q4 2025.
Prime Medicine (PRME) EBT (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of EBT data on file, last reported at -$228.7 million in Q1 2026.
- Quarterly EBT fell 340.77% year-over-year to -$228.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$453.2 million (down 124.21% YoY) and the FY2025 annual result came in at -$204.2 million, down 4.25% from the prior year.
- EBT eased to -$228.7 million in Q1 2026, from -$47.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$24.4 million in Q1 2022 to a low of -$228.7 million in Q1 2026.
- A 5-year average of -$60.1 million and a median of -$47.5 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT soared 35.85% — and 2026, when it tumbled 340.77%.
- Tracing PRME's EBT over 5 years: stood at -$39.5 million in 2022, then plunged by 66.32% to -$65.6 million in 2023, then soared by 35.6% to -$42.3 million in 2024, then dropped by 12.42% to -$47.5 million in 2025, then slumped by 381.22% to -$228.7 million in 2026.
- The last three EBT figures came in at -$228.7 million (Q1 2026), -$47.5 million (Q4 2025), and -$124.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | -216.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -216.13 Mn |
| Mar 31, 2026 | -228.71 Mn |
| Dec 31, 2025 | -47.53 Mn |
| Sep 30, 2025 | -124.40 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.46 Mn |
| Mar 31, 2024 | -45.63 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.82 Mn |
| Jun 30, 2023 | -42.35 Mn |
| Mar 31, 2023 | -39.60 Mn |
| Dec 31, 2022 | -39.47 Mn |
| Sep 30, 2022 | -29.14 Mn |
| Jun 30, 2022 | -29.79 Mn |
| Mar 31, 2022 | -24.37 Mn |
| Dec 31, 2021 | -61.53 Mn |
| Sep 30, 2021 | -18.78 Mn |